Latest news and press releases about PMGC Holdings Inc. (ELAB): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
PMGC Holdings Inc. functions as a biopharmaceutical firm, primarily dedicated to sourcing and advancing innovative aesthetic and therapeutic solutions. Its flagship product, EL-22, is a pioneering engineered probiotic designed to tackle the critical challenge of maintaining muscle mass during weight reduction regimens, especially those utilizing GLP-1 receptor agonists.
Price
| Price | $4.77 |
| Market Cap | $2M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.14 |
| EV / EBITDA | -0.02 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -98.35% |
| Return on Invested Capital | -70.17% |
| Return on Assets | -59.90% |
| Gross Margin | 10.31% |
| Operating Margin | -477.02% |
| Net Margin | -522.97% |
Related companies: ATXI · BCTXZ · DRMA · MLEC · NCEL · NKGN · PBM
Explore sector: Healthcare · Biotechnology
More sections of ELAB: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks